Review



bladder cancer cell lines j82  (Procell Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Procell Inc bladder cancer cell lines j82
    Bladder Cancer Cell Lines J82, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bladder cancer cell lines j82/product/Procell Inc
    Average 90 stars, based on 1 article reviews
    bladder cancer cell lines j82 - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    human bladder cancer cell lines j82  (ATCC)
    96
    ATCC human bladder cancer cell lines j82
    Human Bladder Cancer Cell Lines J82, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder cancer cell lines j82/product/ATCC
    Average 96 stars, based on 1 article reviews
    human bladder cancer cell lines j82 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    bladder cancer cell lines j82  (Procell Inc)
    90
    Procell Inc bladder cancer cell lines j82
    Bladder Cancer Cell Lines J82, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bladder cancer cell lines j82/product/Procell Inc
    Average 90 stars, based on 1 article reviews
    bladder cancer cell lines j82 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    human bladder cancer cell lines j82  (DSMZ)
    94
    DSMZ human bladder cancer cell lines j82
    Homologous recombination (HR) deficiency confers cisplatin and PARP inhibitor sensitivity in bladder cancer cells. (a) Immunoblot showing siRNA-mediated depletion of BRCA2 protein in KU19-19 and <t>J82</t> bladder cancer cell lines. Vinculin is shown as a loading control. (b) Immunofluorescence (IF) microscopy shows loss of radiation-induced Rad51 foci formation in BRCA2-depleted compared to BRCA2-intact bladder cancer cells. (c) Cell viability assays demonstrate increased sensitivity to cisplatin following BRCA2 depletion in bladder cancer cell lines. (d) Cell viability assays demonstrate increased sensitivity to PARP inhibitors olaparib and talazoparib in bladder cancer cell lines. kDa, kilodalton. NTC, non-targeting control. Gy, Gray. MFI, mean fluorescence intensity. *p < 0.01 (IC50 values). Error bars represent standard deviation of data collected from assays performed in triplicate (panel B) or quadruplicate (panels C, D).
    Human Bladder Cancer Cell Lines J82, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bladder cancer cell lines j82/product/DSMZ
    Average 94 stars, based on 1 article reviews
    human bladder cancer cell lines j82 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    bladder cancer cell line j82  (ATCC)
    96
    ATCC bladder cancer cell line j82
    Homologous recombination (HR) deficiency confers cisplatin and PARP inhibitor sensitivity in bladder cancer cells. (a) Immunoblot showing siRNA-mediated depletion of BRCA2 protein in KU19-19 and <t>J82</t> bladder cancer cell lines. Vinculin is shown as a loading control. (b) Immunofluorescence (IF) microscopy shows loss of radiation-induced Rad51 foci formation in BRCA2-depleted compared to BRCA2-intact bladder cancer cells. (c) Cell viability assays demonstrate increased sensitivity to cisplatin following BRCA2 depletion in bladder cancer cell lines. (d) Cell viability assays demonstrate increased sensitivity to PARP inhibitors olaparib and talazoparib in bladder cancer cell lines. kDa, kilodalton. NTC, non-targeting control. Gy, Gray. MFI, mean fluorescence intensity. *p < 0.01 (IC50 values). Error bars represent standard deviation of data collected from assays performed in triplicate (panel B) or quadruplicate (panels C, D).
    Bladder Cancer Cell Line J82, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bladder cancer cell line j82/product/ATCC
    Average 96 stars, based on 1 article reviews
    bladder cancer cell line j82 - by Bioz Stars, 2026-03
    96/100 stars
    		  Buy from Supplier
    human urothelial bladder cancer cell line j82  (Merck KGaA)
    90
    Merck KGaA human urothelial bladder cancer cell line j82
    Homologous recombination (HR) deficiency confers cisplatin and PARP inhibitor sensitivity in bladder cancer cells. (a) Immunoblot showing siRNA-mediated depletion of BRCA2 protein in KU19-19 and <t>J82</t> bladder cancer cell lines. Vinculin is shown as a loading control. (b) Immunofluorescence (IF) microscopy shows loss of radiation-induced Rad51 foci formation in BRCA2-depleted compared to BRCA2-intact bladder cancer cells. (c) Cell viability assays demonstrate increased sensitivity to cisplatin following BRCA2 depletion in bladder cancer cell lines. (d) Cell viability assays demonstrate increased sensitivity to PARP inhibitors olaparib and talazoparib in bladder cancer cell lines. kDa, kilodalton. NTC, non-targeting control. Gy, Gray. MFI, mean fluorescence intensity. *p < 0.01 (IC50 values). Error bars represent standard deviation of data collected from assays performed in triplicate (panel B) or quadruplicate (panels C, D).
    Human Urothelial Bladder Cancer Cell Line J82, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human urothelial bladder cancer cell line j82/product/Merck KGaA
    Average 90 stars, based on 1 article reviews
    human urothelial bladder cancer cell line j82 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Homologous recombination (HR) deficiency confers cisplatin and PARP inhibitor sensitivity in bladder cancer cells. (a) Immunoblot showing siRNA-mediated depletion of BRCA2 protein in KU19-19 and J82 bladder cancer cell lines. Vinculin is shown as a loading control. (b) Immunofluorescence (IF) microscopy shows loss of radiation-induced Rad51 foci formation in BRCA2-depleted compared to BRCA2-intact bladder cancer cells. (c) Cell viability assays demonstrate increased sensitivity to cisplatin following BRCA2 depletion in bladder cancer cell lines. (d) Cell viability assays demonstrate increased sensitivity to PARP inhibitors olaparib and talazoparib in bladder cancer cell lines. kDa, kilodalton. NTC, non-targeting control. Gy, Gray. MFI, mean fluorescence intensity. *p < 0.01 (IC50 values). Error bars represent standard deviation of data collected from assays performed in triplicate (panel B) or quadruplicate (panels C, D).

    Journal: Bladder Cancer

    Article Title: Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer *

    doi: 10.1177/23523735251317865

    Figure Lengend Snippet: Homologous recombination (HR) deficiency confers cisplatin and PARP inhibitor sensitivity in bladder cancer cells. (a) Immunoblot showing siRNA-mediated depletion of BRCA2 protein in KU19-19 and J82 bladder cancer cell lines. Vinculin is shown as a loading control. (b) Immunofluorescence (IF) microscopy shows loss of radiation-induced Rad51 foci formation in BRCA2-depleted compared to BRCA2-intact bladder cancer cells. (c) Cell viability assays demonstrate increased sensitivity to cisplatin following BRCA2 depletion in bladder cancer cell lines. (d) Cell viability assays demonstrate increased sensitivity to PARP inhibitors olaparib and talazoparib in bladder cancer cell lines. kDa, kilodalton. NTC, non-targeting control. Gy, Gray. MFI, mean fluorescence intensity. *p < 0.01 (IC50 values). Error bars represent standard deviation of data collected from assays performed in triplicate (panel B) or quadruplicate (panels C, D).

    Article Snippet: Human bladder cancer cell lines J82 and KU19-19 were purchased from ATCC and DSMZ, respectively.

    Techniques: Homologous Recombination, Western Blot, Control, Immunofluorescence, Microscopy, Fluorescence, Standard Deviation

    Combined activity of MMAE and SN-38 with DNA repair inhibitors. (a) Cytotoxic activity of combining MMAE or SN-38 with ATR inhibition (berzosertib, BERZ), USP1 inhibition (ML323), or PARP inhibition (Olaparib, OLA; talazoparib, TALA) in KU19-19 (top graph) and J82 (bottom graph) bladder cancer cell lines with versus without HR deficiency conferred by BRCA2 depletion. (b) Cytotoxic activity of combining MMAE or SN-38 with ATR inhibition (berzosertib, BERZ), USP1 inhibition (ML323), or PARP inhibition (Olaparib, OLA; talazoparib, TALA) in NER-proficient ( ERCC2 WT) KU19-19 cells versus NER-deficient ( ERCC2 -mutant) KE182 cells (top graph) or NER-proficient (ERCC4 WT) H460 cells versus NER-deficient (ERCC4-deleted) H460 cells (bottom graph). Combination activity is quantified by the combination index (CI, see Methods) with positive log10(CI) values indicative of antagonism and negative log10(CI) values indicative of synergism. HRP, homologous recombination proficient (WT BRCA2); HRD, homologous recombination deficient (BRCA2 depleted); NERP, nucleotide excision repair proficient; NERD, nucleotide excision repair deficient. Error bars represent standard deviation of data collected from assays performed in quadruplicate.

    Journal: Bladder Cancer

    Article Title: Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer *

    doi: 10.1177/23523735251317865

    Figure Lengend Snippet: Combined activity of MMAE and SN-38 with DNA repair inhibitors. (a) Cytotoxic activity of combining MMAE or SN-38 with ATR inhibition (berzosertib, BERZ), USP1 inhibition (ML323), or PARP inhibition (Olaparib, OLA; talazoparib, TALA) in KU19-19 (top graph) and J82 (bottom graph) bladder cancer cell lines with versus without HR deficiency conferred by BRCA2 depletion. (b) Cytotoxic activity of combining MMAE or SN-38 with ATR inhibition (berzosertib, BERZ), USP1 inhibition (ML323), or PARP inhibition (Olaparib, OLA; talazoparib, TALA) in NER-proficient ( ERCC2 WT) KU19-19 cells versus NER-deficient ( ERCC2 -mutant) KE182 cells (top graph) or NER-proficient (ERCC4 WT) H460 cells versus NER-deficient (ERCC4-deleted) H460 cells (bottom graph). Combination activity is quantified by the combination index (CI, see Methods) with positive log10(CI) values indicative of antagonism and negative log10(CI) values indicative of synergism. HRP, homologous recombination proficient (WT BRCA2); HRD, homologous recombination deficient (BRCA2 depleted); NERP, nucleotide excision repair proficient; NERD, nucleotide excision repair deficient. Error bars represent standard deviation of data collected from assays performed in quadruplicate.

    Article Snippet: Human bladder cancer cell lines J82 and KU19-19 were purchased from ATCC and DSMZ, respectively.

    Techniques: Activity Assay, Inhibition, Mutagenesis, Homologous Recombination, Standard Deviation